Consistently, the results of a vemurafenib basket (VE-BASKET) trial, involving n = 62 NSCLC patients, recently confirmed not only the efficacy of this BRAF inhibitor but also its safety profile in advanced-stage NSCLC BRAF exon 15 p.V600-positive patients [124]. Here, BRAF is linked to non-small cell lung carcinoma.